Brain-targeted delivery of losartan through functionalized liposomal nanoparticles for management of neurogenic hypertension.

Richard Nii Lante Lamptey, Chengwen Sun, Jagdish Singh

International journal of pharmaceutics 2023 Apr 25

filter terms:

There is mounting experimental evidence that blocking angiotensin receptor type 1 activity can prevent the occurrence of hypertension in spontaneously hypertensive rats. Studies have proved this strategy via evasive means, such as intracerebrovascular injections, making clinical translation difficult. This study aimed to develop penetratin and transferrin functionalized liposomes as a delivery tool to safely deliver losartan potassium (an angiotensin receptor blocker) to the brain. Penetratin and transferrin functionalized losartan-loaded liposomes were prepared via the post-insertion technique. Losartan-loaded liposomes were cationic, approximately 150 nm in size, entrapping 66.8 ± 1.5% of losartan. All formulations were well tolerated and internalized by primary and cultured cells in 4 h. Further, the ability to deliver losartan potassium across the blood-brain barrier was evaluated in vivo in Wistar Kyoto rats either in solution or when encapsulated within liposomal nanoparticles. Upon intravenous administration, we did not find a detectable amount of losartan in the brain tissue of rats that received free losartan solution. Contrarily, liposome formulations could deliver losartan to the brain, with a brain AUC and mean resident time of 163.304 ± 13.09 and 8.623 h ± 0.66, respectively. In addition, no toxicity was observed in the animals that received the losartan-loaded liposomes. Copyright © 2023 Elsevier B.V. All rights reserved.

Citation

Richard Nii Lante Lamptey, Chengwen Sun, Jagdish Singh. Brain-targeted delivery of losartan through functionalized liposomal nanoparticles for management of neurogenic hypertension. International journal of pharmaceutics. 2023 Apr 25;637:122841